InflaRx N.V. (IFRX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Operating profit | €m | -48 | -37 | ||||||
| Net profit | €m | -34 | -46 | -29 | -43 | -46 | -46 | -39 | -19 |
| EPS reported | € | -0.66 | -0.49 | ||||||
| Operating cashflow per share | € | -0.50 | -0.20 | ||||||
| Capex per share | € | 0.00 | 0.00 | ||||||
| FCF per share | € | -0.51 | -0.20 | ||||||
| Free cash flow | €m | -34 | -24 | ||||||
| Net debt | €m | -46 | -158 | ||||||
| Book value equity | €m | 42 | 146 | ||||||
| Book value per share | € | 0.62 | 1.24 | ||||||
| Number of shares | m | 67.29 | 117.66 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.39 | 0.40 | ||||||
| P/S LTM | x | 1,972.04 | -5,726.34 | ||||||
| P/FCF LTM | x | -1.70 | -2.41 | ||||||
| EV/EBITDA LTM | x | -0.95 | -1.10 | ||||||
| EV/Sales LTM | x | 1,456.61 | -11,290.58 | ||||||
| Earnings Yield LTM | % | -78.89% | -18.87% | ||||||
| FCF Yield | % | -58.84% | -41.43% | ||||||
| Quality | |||||||||
| ROE | % | -109.86% | -58.00% | ||||||
| ROIC | % | -1.14% | -24.89% | ||||||
| Operating margin | % | -1645.3% | +3622.7% | ||||||
| Gross margin | % | -246.78% | +482.02% | ||||||
| FCF/Sales | % | -116026.4% | +237243.1% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -82.31% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -37.92 | -28.77 | ||||||
| Net Debt/EBITDA | x | 0.33 | 3.76 | ||||||
| EBIT/Net interest | x | -1,280.37 | -610.45 | ||||||
| Net debt/market cap | % | +0.44% | +0.10% | ||||||
| Net debt/Equity | x | -1.11 | -1.08 | ||||||
| Gross debt/equity | x | 0.02 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free